Today: 28 June 2026
Browse Category

Biotechnology 23 May 2026 - 27 June 2026

Moderna (NASDAQ:MRNA) price targets draw attention as shares rally into short holiday week

Moderna (NASDAQ:MRNA) price targets draw attention as shares rally into short holiday week

Moderna soared 12.6% Friday on heavy volume after unveiling new in vivo CAR-T pipeline plans, closing at $67.27—52% above the mean analyst target but still 14.5% below Piper Sandler’s new $77 target. The rally followed Science Day updates, even as analysts note the main new asset is preclinical and cash burn continues, with $7.5B cash at March-end and a projected $3B R&D spend for 2026.
27 June 2026
···
uniQure Gets Go-Ahead From FDA for AMT-130 Huntington’s Gene Therapy Application

uniQure shares steady after FDA momentum, Huntington’s filing on radar

uniQure surged 78.4% to $48.16 after the FDA said Phase I/II AMT-130 trial data could support an accelerated-approval filing for its Huntington’s disease gene therapy, with a Biologics License Application planned for Q3 2026; the FDA still requires a confirmatory study and could decide the data are insufficient, leaving the stock’s rally dependent on regulatory follow-through.
18 June 2026
··
Park Ha Biological Technology Stock Surges Premarket as BYAH Volatility Grabs Traders

Park Ha Biological Technology Stock Surges Premarket as BYAH Volatility Grabs Traders

Park Ha Biological Technology’s Nasdaq shares soared 128.57% to $2.40 in Friday premarket after closing down 15.32% at $1.05, capping a volatile week with no new company news; investors await regular-session trading and any SEC filing tied to the company’s $300 million shelf registration as dilution risk and extreme price swings remain central concerns.
12 June 2026
··
CRISPR Therapeutics Jumps 12% in New York Trading

CRISPR Therapeutics Jumps 12% in New York Trading

CRISPR Therapeutics shares soared 11.7% to $58.15 after presenting at the Jefferies Global Healthcare Conference, with sector momentum lifting gene-editing stocks and the SPDR S&P Biotech ETF up 3.0%. Casgevy, its key sickle cell therapy, posted $43 million Q1 revenue, but a $122.9 million net loss and biotech risks mean the rally hinges on investor appetite and upcoming clinical updates.
4 June 2026
·······
Legend Biotech jumps 42% as traders look at results from small cancer study

Legend Biotech jumps 42% as traders look at results from small cancer study

Legend Biotech shares soared 42% to $36.28 after early Phase 1 data showed all six higher-dose patients with relapsed or refractory B-cell non-Hodgkin lymphoma responded to its in vivo CAR-T therapy LB2501, with five complete responses; UBS raised its price target to $49, citing the therapy’s outlook, but the results are early and based on a small group with short follow-up.
3 June 2026
···
Abivax Stock Sees Big After-Hours Moves After Trial Result

Abivax Stock Sees Big After-Hours Moves After Trial Result

Abivax shares plunged 33.7% to $86.01 after hours on Nasdaq despite its ulcerative colitis drug obefazimod hitting the main goal in a 44-week Phase 3 trial. Both 25 mg and 50 mg doses showed over 50% clinical remission versus 10.4% for placebo. No new safety signals reported. Abivax plans a U.S. FDA filing late Q4 2026. Cash reserves stood at €491.6 million at March-end, funding into Q4 2027.
2 June 2026
···
Revolution Medicines Stock Moves Premarket After Pancreatic Cancer Data

Revolution Medicines Stock Moves Premarket After Pancreatic Cancer Data

Revolution Medicines shares rose 1.9% premarket to $157.48 after Phase 3 trial data showed its experimental pill daraxonrasib nearly doubled median survival in pancreatic cancer to 13.2 months vs. 6.7 for chemo. The company, with no approved drugs or revenue, plans to file for FDA approval using a priority voucher. High-grade side effects were less common than chemo. Market cap stood at $31.2 billion.
1 June 2026
···
1 2 3 … 19

Stock Market Today

  • Welltower Stock Gains Attention Amid Surge in US Senior Living Real Estate Capital
    June 28, 2026, 1:38 AM EDT. Welltower, a major US-focused senior living real estate company with a market cap of US$160.5 billion, draws fresh interest as Bridgepoint plans a $1 billion acquisition of Kayne Anderson's real estate platform. The deal, adding $22 billion in medical offices, senior housing and student accommodations, signals growing institutional investment in senior living sectors. Welltower's extensive portfolio includes 2,500 properties across the US, UK, and Canada, primarily in seniors housing. Bridgepoint's expansion into US healthcare real estate could influence market pricing and transaction activity in the sector, potentially benefiting Welltower. Investors should watch how increased capital flows affect the sector's valuation dynamics amid evolving deal flows and funding sources.

Latest articles

Hecla Mining (NYSE:HL) sees stock rebound, volume jumps as silver prices in focus

Hecla Mining (NYSE:HL) sees stock rebound, volume jumps as silver prices in focus

28 June 2026
Hecla Mining surged 5.3 times its average trading volume Friday as index rebalancing drove 112.44 million shares traded, but the stock’s 2.6% weekly drop still beat silver and peer ETFs, signaling company-specific strength; investors now watch if Hecla can hold above $15.54 without rebalancing flows as macro risks loom.
Go toTop